Low Creatinine-to-Cystatin C Ratio Tied to Lower Muscle Volume in Midlife Women
MONDAY, March 31, 2025 -- Among middle-aged women, low creatinine-to-cystatin C ratio (CCR) at baseline is associated with lower fat-free muscle volumes and poorer gait speeds 6.6 years later, according to a study published online March 18 in Menopause.
Darren Yuen Zhang Tan, from the National University of Singapore, and colleagues examined the longitudinal relationship of baseline CCR with muscle volumes measured by magnetic resonance imaging (MRI) and objectively measured muscle strength and physical performance after a follow-up of 6.6 years. Participants included 891 women (baseline mean age, 56.2 ± 6.0 years) who attended baseline and follow-up visits and underwent objectively measured muscle strength and physical performance assessments and MRI.
The researchers observed an association between baseline low CCR and lower MRI-measured muscle volumes and poorer physical function 6.6 years later. After adjustment for covariates, mean fat-free thigh muscle of the low-CCR group was 0.350 L lower than in the high-CCR group. In addition, there were associations seen for the low-CCR group with 0.029 m/s slower mean usual gait and 0.049 m/s slower mean narrow gait speeds. No association was seen for CCR with handgrip strength and repeated chair stands and one-leg stand tests.
"Because both muscle volume and poorer gait speed are constituents of current diagnostic criteria of sarcopenia, CCR may be a tool to help identify midlife women at risk of developing early sarcopenia and associated probability of adverse health outcomes," Stephanie Faubion, M.D., medical director of The Menopause Society, said in a statement. "Regardless of baseline risk, all midlife women should strive to mitigate loss of muscle mass with regular resistance training and adequate dietary protein intake to help prevent frailty as they age."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Elinzanetant Safe, Effective for Moderate-to-Severe Vasomotor Symptoms
TUESDAY, Sept. 30, 2025 -- Elinzanetant, a dual neurokinin-targeted therapy, is effective for treating menopause-associated moderate-to-severe vasomotor symptoms (VMS), according...
Wrist Cooling May Help Manage Vasomotor Symptoms
WEDNESDAY, Sept. 24, 2025 -- Targeted wrist cooling may offer a safe approach for managing vasomotor symptoms, according to a study published online Sept. 20 in Endocrinology...
Age at Start of Estrogen Therapy May Affect Alzheimer Disease Risk
WEDNESDAY, Sept. 24, 2025 -- Estrogen therapy may reduce Alzheimer disease (AD) risk, with lower risk seen in association with early initiation, according to a study presented at...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.